Introduction You may have seen recent reports suggesting a dramatic rise in adverse events and overdoses related to GLP-1 medications such as semaglutide and tirzepatide. Some headlines describe increases of over 1,000%. That number gets attention—but it requires context. Reported GLP-1 exposures by month (2025 YTD). Source: U.S. Poison Control Centers. What the Data Shows Reported exposures have increased—but these reflect calls and reports, not necessarily severe toxicity.
